Towards a vaccine for Cryptococcus neoformans:: principles and caveats

被引:41
作者
Datta, Kausik
Pirofski, Liise-anne
机构
[1] Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA
[2] Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA
关键词
Cryptococcus neoformans; antibody-mediated immunity; vaccine;
D O I
10.1111/j.1567-1364.2006.00073.x
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In the Damage-response framework of microbial pathogenesis, infectious diseases are one outcome of a host-microorganism interaction in a susceptible host. In cryptococcal disease, damage to the host is caused by Cryptococcus neoformans virulence determinants, the nature of the host response, or both. Further, the disease may be acute or reactivated from a latent state. Hence, a vaccine for C. neoformans would need to prevent disease resulting from either acute or reactivated infection. The evidence to support the development of a vaccine for C. neoformans that induces antibody-mediated immunity is discussed herein.
引用
收藏
页码:525 / 536
页数:12
相关论文
共 73 条
[41]   Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen [J].
Kruetzmann, S ;
Rosado, MM ;
Weber, H ;
Germing, U ;
Tournilhac, O ;
Peter, HH ;
Berner, R ;
Peters, A ;
Boehm, T ;
Plebani, A ;
Quinti, I ;
Carsetti, R .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (07) :939-945
[42]   Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis [J].
Larsen, RA ;
Pappas, PG ;
Perfect, J ;
Aberg, JA ;
Casadevall, A ;
Cloud, GA ;
James, R ;
Filler, S ;
Dismukes, WE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (03) :952-958
[43]   Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan [J].
Maitta, RW ;
Datta, K ;
Pirofski, UA .
VACCINE, 2004, 22 (29-30) :4062-4068
[44]   Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles [J].
Maitta, RW ;
Datta, K ;
Chang, Q ;
Luo, RX ;
Witover, B ;
Subramaniam, K ;
Pirofski, LA .
INFECTION AND IMMUNITY, 2004, 72 (08) :4810-4818
[45]   Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice [J].
Maitta, RW ;
Datta, K ;
Lees, A ;
Belouski, SS ;
Pirofski, LA .
INFECTION AND IMMUNITY, 2004, 72 (01) :196-208
[46]   Protective efficacy of antigenic fractions in mouse models of cryptococcosis [J].
Mansour, MK ;
Yauch, LE ;
Rottman, JB ;
Levitz, SM .
INFECTION AND IMMUNITY, 2004, 72 (03) :1746-1754
[47]   Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates:: Implications for vaccine development [J].
May, RJ ;
Beenhouwer, DO ;
Scharff, MD .
JOURNAL OF IMMUNOLOGY, 2003, 171 (09) :4905-4912
[48]   Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice [J].
Mendez, MJ ;
Green, LL ;
Corvalan, JRF ;
Jia, XC ;
MaynardCurrie, CE ;
Yang, XD ;
Gallo, ML ;
Louie, DM ;
Lee, DV ;
Erickson, KL ;
Luna, J ;
Roy, CMN ;
Abderrahim, H ;
Kirschenbaum, F ;
Noguchi, M ;
Smith, DH ;
Fukushima, A ;
Hales, JF ;
Finer, MH ;
Davis, CG ;
Zsebo, KM ;
Jakobovits, A .
NATURE GENETICS, 1997, 15 (02) :146-156
[49]   CpG oligodeoxynucleotides promote the host protective response against infection with Cryptococcus neoformans through induction of interferon-gamma production by CD4+ T cells [J].
Miyagi, K ;
Kawakami, K ;
Kinjo, Y ;
Uezu, K ;
Kinjo, T ;
Nakamura, K ;
Saito, A .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2005, 140 (02) :220-229
[50]   Peptide mimotopes as surrogate antigens of carbohydrates in vaccine discovery [J].
Monzavi-Karbassi, B ;
Cunto-Amesty, G ;
Luo, P ;
Kieber-Emmons, T .
TRENDS IN BIOTECHNOLOGY, 2002, 20 (05) :207-214